EPCORE DLBCL-2: Epcoritamab in Combination with R-CHOP vs R-CHOP Alone as First Line Treatment
Condition: Diffuse Large B-Cell Lymphoma
Sponsor: AbbVie
Full Title
Protocol M20-621: A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Study Treatment
CD20xCD3 bispecific antibody Epcoritamab + R-CHOP vs R-CHOP alone
Eligibility/Info
- Newly diagnosed diffuse large b-cell lymphoma
- No history of treatment for DLBCL
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
